Market Newsdesk

BOSTON, April 19, 2021 /PRNewswire/ — Haemonetics Corporation (NYSE: HAE) (“Haemonetics” or the “Company”), a global medical technology company focused on delivering innovative medical solutions to drive better patient outcomes, today announced that CSL Plasma, Ltd. (“CSL”) has informed Haemonetics of its intent not to renew its Supply Agreement with Haemonetics for the use of PCS2^® Plasma Collection System devices and the purchase of disposable plasmapheresis kits in the U.S. following the expiration of the current term in June 2022. Haemonetics was informed that the decision was based on changes in CSL’s internal strategy and was not related to product or service quality.

This notice of intent not to renew is specific to Haemonetics’ plasmapheresis equipment and disposables Supply Agreement for CSL’s U.S. plasma collection centers. In fiscal year 2020, Haemonetics revenue under this Supply Agreement was $117 million, or 11.8% of total Company revenue, with a gross margin similar to total Company adjusted gross margin. The Company expects to incur an approximately $25 million one-time impairment relating to disposables manufacturing equipment and an estimated $7 million in additional expenses in the fourth quarter of fiscal 2021 in relation to this announcement. Haemonetics remains committed to supporting CSL in other geographies and capacities, representing approximately 1% of total Company revenue in fiscal year 2020, and will continue to support CSL’s plans to roll out NexSys PCS^® plasmapheresis devices in Europe under the recently executed agreement with CSL.

“We have a long-standing relationship with CSL and while we are disappointed by this decision we appreciate the advance notice,” said Chris Simon, Haemonetics’ President and CEO. “We have taken a series of actions over the past five years to strengthen Haemonetics’ financial health and believe that our organization has the agility to navigate these changes. We are confident in our ability to continue to generate positive cash flow as we pursue our strategies to deliver shareholder value.”

Haemonetics continues to believe in the value proposition of its NexSys PCS^® and Persona^® technologies, supported by real world data, and remains committed to delivering these technologies to its customers and pursuing additional innovation to further improve plasma collection. The Company also reaffirms its expectation of 8-10% average long term growth in the U.S. source plasma collections market.

As previously noted, the current term of the Supply Agreement expires on June 30, 2022.  The Supply Agreement also provides CSL the right to extend the agreement until June 30, 2023 with notice of renewal to be given no later than December 31, 2021. 

The Company intends to provide additional details about this announcement on its fourth quarter and fiscal year 2021 earnings call in May 2021.

About Haemonetics
Haemonetics (NYSE: HAE) is a global healthcare company dedicated to providing a suite of innovative medical products and solutions for customers, to help them improve patient care and reduce the cost of healthcare. Our technology addresses important medical markets: blood and plasma component collection, the surgical suite and hospital transfusion services. To learn more about Haemonetics, visit www.haemonetics.com.

Cautionary Note Regarding Forward Looking Statements
Any statements contained in this press release that do not describe historical facts may constitute forward-looking statements. Forward-looking statements in this press release may include, without limitation, statements regarding (i) CSL’s notice of intent not to renew the Supply Agreement between CSL and Haemonetics described above (the “Supply Agreement”); (ii) the anticipated consequences of non-renewal of the Supply Agreement, including the anticipated impairment charge and expenses to be incurred, and the ability of Haemonetics to respond to these changes; (iii) future positive cash flow and the pursuit of strategies to deliver shareholder value; (iv) the potential of Haemonetics’ plasma products, including NexSys PCS^® and Persona^®, (v) the anticipated long-term growth in the U.S. source plasma collections market, and (vi) the assumptions underlying or relating to any statement described in points (i) to (v) above. Such forward-looking statements are not meant to predict or guarantee actual results, performance, events or circumstances and may not be realized because they are based upon the Company’s current projections, plans, objectives, beliefs, expectations, estimates and assumptions and are subject to a number of risks and uncertainties and other influences.

Actual results and the timing of certain events and circumstances may differ materially from those described by the forward-looking statements as a result of these risks and uncertainties. Factors that may influence or contribute to the inaccuracy of the forward-looking statements or cause actual results to differ materially from expected or desired results may include, without limitation, the possibility that CSL may determine to renew the Supply Agreement for additional periods; the impact of the COVID-19 pandemic, including the scope and duration of the outbreak and government actions and restrictive measures implemented in response; the availability and demand for the Company’s products; the Company’s ability to implement as planned and realize estimated cost savings from the Operational Excellence Program; the Company’s ability to execute business continuity plans; risks arising from the Company’s acquisition of Cardiva, including any failure to realize the anticipated benefits of the transaction; technological advances in the medical field and standards for transfusion medicine and the Company’s ability to successfully offer products that incorporate such advances and standards; product quality; market acceptance; regulatory uncertainties, including in the receipt or timing of regulatory approvals; the effect of economic and political conditions; the impact of competitive products and pricing; blood product reimbursement policies and practices; and the effect of industry consolidation as seen in the plasma market. These and other factors are identified and described in more detail in the Company’s periodic reports and other filings with the U.S. Securities and Exchange Commission. The Company does not undertake to update these forward-looking statements.

 

View original content to download multimedia:http://www.prnewswire.com/news-releases/haemonetics-provides-update-on-us-plasma-business-301271066.html

SOURCE Haemonetics Corporation

ATLANTA, April 19, 2021 /PRNewswire/ — Preferred Apartment Communities, Inc. (NYSE: APTS) (“PAC” or the “Company”) today announced that the Company has entered into an agreement to sell a portfolio of seven office properties and one office real estate loan investment to Highwoods Properties, Inc. (NYSE: HIW) for an aggregate purchase price of $717.5 million, including the assumption of debt.  The transactions are expected to close in the third quarter of 2021 and are subject to customary closing conditions.  The transactions have been unanimously approved by the Company’s Board of Directors.  Highwoods is posting $50 million of earnest money deposits that are non-refundable except in limited circumstances. The portfolio was marketed by JLL.

“We are very pleased to announce this strategic agreement to sell the substantial majority of our office portfolio to Highwoods Properties. This sale will build upon our strategy to simplify our business platform that commenced with the sale of our student housing portfolio in the 2nd half of 2020.  Upon closing, PAC’s real estate portfolio will be further streamlined with an increased primary weighting on our core Class A suburban Sunbelt multifamily business and our complementary 100% grocery-anchored Sunbelt retail investments.  As we did with the student housing sale, we intend to utilize the cash proceeds generated from this sale (i) to continue to realign our balance sheet through calls and/or redemptions of our Series A preferred shares, (ii) to continue growing our core portfolio through acquisitions and real estate loan investments, and (iii) for other corporate purposes.  Highwoods has demonstrated their commitment to this significant transaction and their sector experience throughout the process, and both groups worked very well together during the due diligence phase,” stated Joel T. Murphy, Preferred Apartment Communities’ President and Chief Executive Officer. 

Mr. Murphy continued, “We will remain focused on maximizing the value of our few remaining office assets through prudent asset management and then effect a complete exit from the office sector through a controlled and well-navigated disposition process over time.  We are grateful to the entire team at PAC for their hard work and commitment throughout this process, and particularly so to the professionals in our office group who assembled and operated this high quality portfolio of assets over these past five years.”

Portfolio

The portfolio includes seven properties and one real estate loan investment:

• 150 Fayetteville, a 560,000 SF office tower located in Raleigh, NC
• Capitol Towers, a 479,000 SF two-building office tower complex located in Charlotte, NC
• CAPTRUST Tower, a 300,000 SF office tower located in Raleigh, NC
• Morrocroft Centre, a 291,000 SF three-building office complex located in Charlotte, NC
• Encore Center, a 111,000 SF office complex located in Atlanta, GA
• 8 West (real estate loan investment), a 195,000 SF office property located in Atlanta, GA
• Armour Yards, a 187,000 SF creative office complex located in Atlanta, GA
• 251 Armour, a 36,000 SF creative office complex located in Atlanta, GA

As part of the transaction, PAC will separately market Armour Yards and 251 Armour for sale to a third party.  The Armour Yards and 251 Armour transaction may close earlier or later than the third quarter of 2021 depending on whether PAC chooses to sell them to a third party purchaser or requires Highwoods to purchase them (with an outside date in the first quarter of 2022).

Transaction Benefits:

• Continued Simplification: Company’s revenue will be derived primarily from multifamily properties and multifamily real estate loan investments, with the remainder coming from grocery anchored retail and the remaining office properties. The Company’s intention is to fully exit the office asset class having exited student housing in 2020.

• Further Realignment of the Balance Sheet: The Company expects to utilize a portion of the proceeds to redeem a portion of its 6.00% Series A Redeemable Preferred Stock.

• Allows for Capital Recycling into Core Multifamily Business: The Company intends to largely redeploy the remainder of the proceeds to grow its core suburban Sunbelt Class A multifamily business through PAC’s proprietary acquisition channels, including real estate loan investments, and for other corporate purposes.

The financial impacts of these planned disposition and investment activities were not included in the Company’s 2021 Core FFO per share guidance released on March 1, 2021. The Company anticipates that the transaction will reduce Core FFO following closing but this may be offset to some extent based on the use of the proceeds, the timing of redeployment of proceeds, and G&A savings. The Company will provide updated 2021 Core FFO guidance as part of its first quarter earnings release on May 10, 2021.

JLL acted as exclusive real estate advisor, Goldman Sachs & Co. LLC acted as exclusive financial advisor, and King & Spalding LLP acted as legal advisor to PAC.

About Preferred Apartment Communities, Inc.

Preferred Apartment Communities, Inc. (NYSE: APTS) is a real estate investment trust engaged primarily in the ownership and operation of Class A multifamily properties, with select investments in grocery-anchored shopping centers and Class A office buildings. Preferred Apartment Communities’ investment objective is to generate attractive, stable returns for stockholders by investing in income-producing properties and acquiring or originating real estate loans. As of December 31, 2020, the Company owned or was invested in 116 properties in 13 states, predominantly in the Southeast region of the United States. Learn more at www.pacapts.com.

Forward-Looking Statements

This press release may contain forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. These statements may be identified by the use of forward-looking terminology such as “may”, “trend”, “will”, “expects”, “plans”, “estimates”, “anticipates”, “projects”, “intends”, “believes”, “goals”, “objectives”, “outlook” and similar expressions.  Because such statements include risks, uncertainties and contingencies, actual results may differ materially from the expectations, intentions, beliefs, plans or predictions of the future expressed or implied by such forward-looking statements, including risks related to the closing of the transaction and timing thereof. These risks, uncertainties and contingencies include, but are not limited to, (a) the completion of the transaction described in this press release, (b) the impact of this transaction and the contemplated investment of the sale proceeds and (c) those disclosed in PAC’s filings with the Securities and Exchange Commission. PAC undertakes no obligation to update these forward-looking statements to reflect events or circumstances after the date hereof or to reflect the occurrence of unanticipated events, except as may be required by law.

Additional Information

The SEC has declared effective the registration statement (including prospectus) filed by the Company for each of the offerings to which this communication may relate.  Before you invest, you should read the final prospectus, and any prospectus supplements, forming a part of the registration statement and other documents the Company has filed with the SEC for more complete information about the Company and the offering to which this communication may relate.  In particular, you should carefully read the risk factors described in the final prospectus and in any related prospectus supplement and in the documents incorporated by reference in the final prospectus and any related prospectus supplement to which this communication may relate. You may obtain these documents for free by visiting EDGAR on the SEC website at www.sec.gov.  Alternatively, the Company or its dealer manager, Preferred Capital Securities, LLC, with respect to its Series A1/M1 Redeemable Preferred Stock Offering, will arrange to send you a prospectus if you request it by calling John A. Isakson at (770) 818-4109, 3284 Northside Parkway NW, Suite 150, Atlanta, Georgia 30327.

The Series A1/M1 Redeemable Preferred Stock Offering prospectus, dated October 22, 2019, can be accessed through the following link:

https://www.sec.gov/Archives/edgar/data/1481832/000148183219000097/a424b5-2019seriesamshares.htm

View original content:http://www.prnewswire.com/news-releases/preferred-apartment-communities-inc-continues-simplification-strategy-with-agreement-for-transformational-office-portfolio-sale-301271086.html

SOURCE Preferred Apartment Communities, Inc.

SILVER SPRING, Md. and RESEARCH TRIANGLE PARK, N.C., April 19, 2021 /PRNewswire/ — United Therapeutics Corporation (Nasdaq: UTHR) today announced the submission of a new drug application (NDA) to the U.S. Food and Drug Administration (FDA) for Tyvaso DPI™, a novel dry powder inhalation formulation of treprostinil, for the treatment of pulmonary arterial hypertension (PAH; WHO Group 1 pulmonary hypertension) and pulmonary hypertension associated with interstitial lung disease (PH-ILD; WHO Group 3 pulmonary hypertension). There are approximately 45,000 treated PAH patients in the U.S. and United Therapeutics estimates at least 30,000 treatable PH-ILD patients in the U.S.

The submission includes the results of the recently-completed BREEZE clinical study evaluating the use of Tyvaso DPI in PAH patients transitioning from Tyvaso^® (treprostinil) Inhalation Solution, along with additional pharmacokinetic data from a study in healthy volunteers.

“In the BREEZE and pharmacokinetic studies, Tyvaso DPI demonstrated safety, tolerability, and a comparable pharmacokinetic profile to nebulized Tyvaso Inhalation Solution,” said Leigh Peterson, Ph.D., Senior Vice President, Product Development at United Therapeutics. “If approved by the FDA, we expect Tyvaso DPI will provide an advancement in the delivery of inhaled treprostinil therapy.”

“Since our founding, we’ve worked hard to ensure our patients have ample choices to deliver treprostinil in various ways to suit their individual needs,” said Gil Golden, M.D., Ph.D., Chief Medical Officer of United Therapeutics. “If approved, Tyvaso DPI will enable patients to go about their day with just a small breath­-actuated, dry powder inhaler that easily fits inside a pocket and requires no batteries or external power source to operate.”

“We’re excited for the potential for Tyvaso DPI to be one of our next product launches, assuming a timely approval in December of this year,” said Michael Benkowitz, President and Chief Operating Officer of United Therapeutics. “The patient choice afforded by Tyvaso DPI, if approved, will help us achieve our goal of doubling the number of patients on Tyvaso therapy by the end of 2022. We remain committed to investigating, innovating, and delivering multiple therapies and treatments designed to help our patients manage their conditions.”

United Therapeutics has applied a priority review voucher to the NDA that could provide for an FDA decision by December 2021. The FDA must first accept the application for review and issue a formal decision date in accordance with the Prescription Drug User Fee Act.

Tyvaso DPI is an investigational therapy that is not approved for any use in any country or indication and the Tyvaso DPI tradename is pending final FDA review. United Therapeutics expects to present data from the BREEZE study and the pharmacokinetic study in healthy volunteers at upcoming medical conferences and in forthcoming scientific publications.

About Tyvaso DPI™
Tyvaso DPI™ is an investigational drug-device combination therapy comprised of a dry powder formulation of treprostinil and a small, portable, dry powder inhaler. If approved, Tyvaso DPI is expected to provide a more convenient method of administration compared with traditional nebulized Tyvaso^® therapy. United Therapeutics is developing Tyvaso DPI under a collaboration and license agreement with MannKind Corporation (Nasdaq: MNKD). Tyvaso DPI incorporates the dry powder formulation technology and Dreamboat^® inhalation device technology used in MannKind’s Afrezza^® (insulin human) Inhalation Powder product, which was approved by the FDA in 2014.

United Therapeutics and MannKind are also developing BluHale^®, a Bluetooth-connected accessory for the Tyvaso DPI inhaler with a companion mobile application intended to help the patient track information about inhaler use.

About TYVASO^® (treprostinil) Inhalation Solution

INDICATION

TYVASO (treprostinil) is a prostacyclin mimetic indicated for the treatment of:

• Pulmonary arterial hypertension (PAH; WHO Group 1) to improve exercise ability. Studies establishing effectiveness predominately included patients with NYHA Functional Class III symptoms and etiologies of idiopathic or heritable PAH (56%) or PAH associated with connective tissue diseases (33%).

  The effects diminish over the minimum recommended dosing interval of 4 hours; treatment timing can be adjusted for planned activities.

  While there are long-term data on use of treprostinil by other routes of administration, nearly all controlled clinical experience with inhaled treprostinil has been on a background of bosentan (an endothelin receptor antagonist) or sildenafil (a phosphodiesterase type 5 inhibitor). The controlled clinical experience was limited to 12 weeks in duration.

• Pulmonary hypertension associated with interstitial lung disease (PH-ILD; WHO Group 3) to improve exercise ability. The study establishing effectiveness predominately included patients with etiologies of idiopathic interstitial pneumonia (IIP) (45%) inclusive of idiopathic pulmonary fibrosis (IPF), combined pulmonary fibrosis and emphysema (CPFE) (25%), and WHO Group 3 connective tissue disease (22%).

IMPORTANT SAFETY INFORMATION

WARNINGS AND PRECAUTIONS

• TYVASO is a pulmonary and systemic vasodilator. In patients with low systemic arterial pressure, TYVASO may produce symptomatic hypotension.
• TYVASO inhibits platelet aggregation and increases the risk of bleeding.
• Co-administration of a cytochrome P450 (CYP) 2C8 enzyme inhibitor (e.g., gemfibrozil) may increase exposure (both C_max and AUC) to treprostinil. Co-administration of a CYP2C8 enzyme inducer (e.g., rifampin) may decrease exposure to treprostinil. Increased exposure is likely to increase adverse events associated with treprostinil administration, whereas decreased exposure is likely to reduce clinical effectiveness.

DRUG INTERACTIONS/SPECIFIC POPULATIONS

• The concomitant use of TYVASO with diuretics, antihypertensives, or other vasodilators may increase the risk of symptomatic hypotension.
• Human pharmacokinetic studies with an oral formulation of treprostinil (treprostinil diolamine) indicated that co-administration of the cytochrome P450 (CYP) 2C8 enzyme inhibitor, gemfibrozil, increases exposure (both C_max and AUC) to treprostinil. Co-administration of the CYP2C8 enzyme inducer, rifampin, decreases exposure to treprostinil. It is unclear if the safety and efficacy of treprostinil by the inhalation route are altered by inhibitors or inducers of CYP2C8.
• Limited case reports of treprostinil use in pregnant women are insufficient to inform a drug-associated risk of adverse developmental outcomes. However, pulmonary arterial hypertension is associated with an increased risk of maternal and fetal mortality. There are no data on the presence of treprostinil in human milk, the effects on the breastfed infant, or the effects on milk production.
• Safety and effectiveness in pediatric patients have not been established.
• Across clinical studies used to establish the effectiveness of TYVASO in patients with PAH and PH–ILD, 268 (47.8%) patients aged 65 years and over were enrolled. The treatment effects and safety profile observed in geriatric patients were similar to younger patients. In general, dose selection for an elderly patient should be cautious, reflecting the greater frequency of hepatic, renal, or cardiac dysfunction, and of concomitant diseases or other drug therapy.

ADVERSE REACTIONS

• Pulmonary Arterial Hypertension (WHO Group 1)
  In a 12-week, placebo-controlled study (TRIUMPH I) of 235 patients with PAH (WHO Group 1 and nearly all NYHA Functional Class III), the most common adverse reactions seen with TYVASO in ≥4% of PAH patients and more than 3% greater than placebo in the placebo-controlled study were cough (54% vs 29%), headache (41% vs 23%), throat irritation/pharyngolaryngeal pain (25% vs 14%), nausea (19% vs 11%), flushing (15% vs <1%), and syncope (6% vs <1%). In addition, adverse reactions occurring in ≥4% of patients were dizziness and diarrhea.

• Pulmonary Hypertension Associated with ILD (WHO Group 3)
  In a 16-week, placebo-controlled study (INCREASE) of 326 patients with PH-ILD (WHO Group 3), adverse reactions were similar to the experience in studies of PAH.

Please see Full Prescribing Information, the TD-100 and TD-300 TYVASO^® Inhalation System Instructions for Use manuals, and other additional information at www.tyvaso.com or call 1–877–UNITHER (1-877-864-8437).

United Therapeutics: Enabling Inspiration
United Therapeutics Corporation focuses on the strength of a balanced, value-creating biotechnology model. We are confident in our future thanks to our fundamental attributes, namely our obsession with quality and innovation, the power of our brands, our entrepreneurial culture, and our bioinformatics leadership. We also believe that our determination to be responsible citizens – having a positive impact on patients, the environment, and society – will sustain our success in the long term.

Through our wholly owned subsidiary, Lung Biotechnology PBC, we are focused on addressing the acute national shortage of transplantable lungs and other organs with a variety of technologies that either delay the need for such organs or expand the supply. Lung Biotechnology is the first public benefit corporation subsidiary of a public biotechnology or pharmaceutical company.

Please visit unither.com to learn more.

Forward-looking Statements
Statements included in this press release that are not historical in nature are “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements include, among others, statements relating to the potential for the approval of Tyvaso DPI and the timing of any such approval, its potential benefits to patients, our goal of doubling the number of patients being treated with Tyvaso by 2022, our ability to create value and sustain our success in the long-term, as well as our efforts to develop technologies that either delay the need for transplantable organs or expand the supply of transplantable organs. These forward-looking statements are subject to certain risks and uncertainties, such as those described in our periodic reports filed with the Securities and Exchange Commission, that could cause actual results to differ materially from anticipated results. Consequently, such forward-looking statements are qualified by the cautionary statements, cautionary language and risk factors set forth in our periodic reports and documents filed with the Securities and Exchange Commission, including our most recent Annual Report on Form 10-K, Quarterly Reports on Form 10-Q, and Current Reports on Form 8-K. We claim the protection of the safe harbor contained in the Private Securities Litigation Reform Act of 1995 for forward-looking statements. We are providing this information as of April 19, 2021, and assume no obligation to update or revise the information contained in this press release whether as a result of new information, future events or any other reason.

TYVASO is a registered trademark of United Therapeutics Corporation.

TYVASO DPI is a trademark of United Therapeutics Corporation.

AFREZZA, BLUHALE, and DREAMBOAT are registered trademarks of MannKind Corporation.

For Further Information Contact:
Dewey Steadman at (202) 919-4097
Email: [email protected]   

View original content:http://www.prnewswire.com/news-releases/united-therapeutics-announces-submission-of-tyvaso-dpi-new-drug-application-to-fda-301271030.html

SOURCE United Therapeutics Corporation

VANCOUVER, BC, April 19, 2021 /CNW/ – Treatment.com (CSE: TRUE) announced today its common shares have been approved for listing on the Canadian Securities Exchange (CSE) and will begin trading under the symbol “TRUE”.

“We are a fast-growing technology company fueling innovation in the healthcare industry. Our mission is to keep everyone healthy. Our team has spent years developing the smartest AI health assessment trained to think like a doctor and worked with world-class consumer research agencies to inform our first product, Cara,” said John Fraser, CEO of Treatment.com. “We thank our doctors, researchers and engineers for their groundbreaking work and look forward to trading on the CSE to achieve our ambitious growth plans.”

About Treatment.com

Treatment.com is a disruptive healthcare technology startup that is harnessing the power of AI to help Canadians improve their health through personalized recommendations and insights. Based in Vancouver, the company spent the last five years working with a team of world-class doctors, engineers, mathematicians, and AI specialists to develop a complex AI engine that leverages the most robust, personalized data to generate highly predictive and accurate insights. Treatment.com is the parent company of Cara. This summer, Cara will be empowering Canadians to take control of their health with the launch of an innovative mobile app powered by this exclusive AI engine.

For more investor information on Treatment.com please visit https://treatment.com/investors/.

Forward Looking Statement

This news release contains forward-looking statements relating to the future operations of Treatment.com, International, Inc. (Treatment) and other statements that are not historical facts. Forward-looking statements are often identified by terms such as “will”, “may”, “should”, “anticipate”, “expects” and similar expressions. All statements other than statements of historical fact, included in this release, including, without limitation, statements regarding the future plans and objectives of Treatment, are forward-looking statements that involve risks and uncertainties. There can be no assurance that such statements will prove to be accurate and actual results and future events could differ materially from those anticipated in such statements. Important factors that could cause actual results to differ materially from Treatment’s expectations include other risks detailed from time to time in the filings made by Treatment with securities regulators.

The reader is cautioned that assumptions used in the preparation of any forward-looking information may prove to be incorrect. Events or circumstances may cause actual results to differ materially from those predicted, as a result of numerous known and unknown risks, uncertainties, and other factors, many of which are beyond the control of Treatment. The reader is cautioned not to place undue reliance on any forward-looking information. Such information, although considered reasonable by management at the time of preparation, may prove to be incorrect and actual results may differ materially from those anticipated. Forward-looking statements contained in this news release are expressly qualified by this cautionary statement. The forward-looking statements contained in this news release are made as of the date of this news release and Treatment will only update or revise publicly the included forward-looking statements as expressly required by Canadian securities law.

SOURCE Treatment.com

SOUTH SAN FRANCISCO, Calif., April 19, 2021 /PRNewswire/ — IDEAYA Biosciences, Inc. (NASDAQ: IDYA), a synthetic lethality-focused precision medicine oncology company committed to the discovery and development of targeted therapeutics, announced the agenda for its inaugural Synthetic Lethality Investor Day. The event will be held virtually on Tuesday, April 20, 2021, at 1:00 pm – 3:00 pm ET (10:00 am – 12:00 noon PT). The agenda will include scientific presentations from IDEAYA, GlaxoSmithKline (GSK) and several key opinion leaders.

Presenters

• Alan D’Andrea, M.D., Director, Center of DNA Damage and Repair, Dana Farber Cancer Institute of Harvard Medical School
• William Sellers, M.D., Core Institute Member and Director of the Cancer Program of the Broad Institute of MIT and Harvard
• Benjamin Schwartz, Ph.D., Vice President, Head of Oncology Synthetic Lethality Research Unit, GlaxoSmithKline (GSK)
• Yujiro Hata, President and Chief Executive Officer, IDEAYA Biosciences
• Michael Dillon, Ph.D., SVP and Chief Scientific Officer, IDEAYA Biosciences
• Mark Lackner, Ph.D., SVP and Head of Biology and Translational Sciences, IDEAYA Biosciences
• Matt Maurer, M.D., VP and Head of Clinical Oncology and Medical Affairs, IDEAYA Biosciences

Program Agenda (ET)

• 1:00 pm – Welcome and Introduction
• Yujiro Hata
• 1:10 pm – Synthetic Lethality: Emerging Area within Precision Medicine and GSK-IDEAYA Partnership
• Ben Schwartz (GSK)
• 1:20 pm – IDE397: Targeting MAT2A in MTAP-Deleted Tumors
• Bill Sellers (Broad), Mark Lackner, Matt Maurer
• 1:50 pm – Werner Helicase (Roundtable): Compelling Synthetic Lethality Target
• Introduction: Ben Schwartz (GSK)
• Panelists:Bill Sellers (Broad), Mike Dillon, Ben Schwartz
• Moderator: Yujiro Hata
• 2:10 pm – Pol Theta: Key Target in MMEJ DNA Damage Repair Pathway
• Alan D’Andrea (Harvard), Mike Dillon, Ben Schwartz (GSK)
• 2:30 pm – PARG: Novel Target in Clinically Validated Pathway
• Mike Dillon, Mark Lackner
• 2:45 pm – Analyst Q&A / Closing
• Yujiro Hata
• 3:00 pm – Adjourn

Registration for the IDEAYA Synthetic Lethality Investor Day and additional information on the event is available on IDEAYA’s website at https://ir.ideayabio.com/events.

About IDEAYA Biosciences
IDEAYA is a synthetic lethality-focused precision medicine oncology company committed to the discovery and development of targeted therapeutics for patient populations selected using molecular diagnostics. IDEAYA’s approach integrates capabilities in identifying and validating translational biomarkers with drug discovery to select patient populations most likely to benefit from its targeted therapies. IDEAYA is applying its early research and drug discovery capabilities to synthetic lethality – which represents an emerging class of precision medicine targets. 

Forward-Looking Statements
This press release contains forward-looking statements, including, but not limited to, statements related to the timing, content and participants of the Synthetic Lethality Investor Day. Such forward-looking statements involve substantial risks and uncertainties that could cause IDEAYA’s preclinical and clinical development programs, future results, performance or achievements to differ significantly from those expressed or implied by the forward-looking statements. Such risks and uncertainties include, among others, the uncertainties inherent in the drug development process, including IDEAYA’s programs’ early stage of development, the process of designing and conducting preclinical and clinical trials, the regulatory approval processes, the timing of regulatory filings, the challenges associated with manufacturing drug products, IDEAYA’s ability to successfully establish, protect and defend its intellectual property, the effects on IDEAYA’s business of the worldwide COVID-19 pandemic, and other matters that could affect the sufficiency of existing cash to fund operations. IDEAYA undertakes no obligation to update or revise any forward-looking statements. For a further description of the risks and uncertainties that could cause actual results to differ from those expressed in these forward-looking statements, as well as risks relating to the business of IDEAYA in general, see the IDEAYA Annual Report for the year ended December 31, 2020 on Form 10-K filed on March 23, 2021 and any current and periodic reports filed with the U.S. Securities and Exchange Commission.   

View original content to download multimedia:http://www.prnewswire.com/news-releases/ideaya-biosciences-announces-agenda-for-inaugural-synthetic-lethality-investor-day-on-tuesday-april-20-2021-301271007.html

SOURCE IDEAYA Biosciences, Inc.

VINEYARD, Utah, April 19, 2021 /PRNewswire/ — Today, Grōv Technologies announced it has signed a definitive sales agreement with River Ranch Dairy to help further their goal of becoming more sustainable and drought resistant through the adoption of Grōv’s automated indoor feed technology. Under the terms of the agreement River Ranch will purchase an on-premises indoor vertical animal feed production center which will produce fresh Grōv HDN Superfeed™, using less than 5% of the water of traditional farming.

At the core of the Grōv-River Ranch Feed Center will be the Olympus Tower Farm platform. One Olympus Tower takes up only 857 square feet and can produce 6,000 pounds of Grōv HDN Superfeed daily, replacing between 35-50 acres of farmland, using zero herbicides or pesticides.

“Reducing both our water usage and becoming more sustainable is essential for the long-term economic health of our farm and the environment,” said Jack de Jong, River Ranch Dairy owner and operator.  “In addition to sustainability, the health and welfare of our animals is one of our top priorities. We believe feeding our animals Grōv’s clean fresh “Superfeed” wheatgrass holds the promise to boost the health and productivity of our herd.”

The River Ranch Dairy is home to 10,000 animals located in California’sCentral Valley, the highest and most concentrated milk production area in the U.S. The five-county region has over 1.3 million cows. The new Grōv-River Ranch Feed Center will be located near the annual World Ag Expo in Tulare, California, attracting over 100,000 visitors, conveniently showcasing Grōv’s technology to visitors from around the globe. 

“As changing climates and water shortages increase, dairy and beef farmers will need to be equipped with technology and science that will help them feed growing populations and also care for the health and welfare of their animals,” said Steve Lindsley, president of Grōv Technologies. “We are honored to welcome Jack, who comes from a rich heritage of dairy and Ag expertise, to the Grōv family.”

The Grōv-River Ranch Dairy Feed Center is currently in the permitting and design phase with completion anticipated later this year.

In ongoing trials conducted over the past year, dairy animals that were fed with Grōv HDN Superfeed maintained milk production while eating less dry matter, thus improving overall feed efficiency. Trials were conducted at Bateman Mosida Farms, Utah’s largest dairy.

For more information about Grōv Technologies and its Olympus Tower Farm, please visit www.grovtech.com. Grōv welcomes individuals who want to come visit their facility, as long as they follow social distancing guidelines.

About Grōv Technologies, LLC  
Grōv Technologies is pioneering automated controlled environment agriculture (CEA) science and technology to help meet the demands of global food security. The company has developed enterprise scale systems and growing protocols to consistently produce high-density nutrient feed, or HDN Superfeed™. Grōv enables operators to sustainably grow feed, improve animal health, produce better products and increase profits. Grōv is wholly owned by Nu Skin Enterprises, Inc. (NYSE: NUS), which empowers innovative companies with sustainable solutions, opportunities, technologies, and life-improving values.

Grōv™, Grōv HDN Superfeed™ and Olympus Tower Farm™, are trademarks of Grōv Technologies™. 

View original content to download multimedia:http://www.prnewswire.com/news-releases/grv-technologies-and-california-based-river-ranch-dairy-enter-definitive-agreement-to-build-world-class-automated-indoor-feed-production-center-301270985.html

SOURCE Grōv Technologies

CALABASAS, Calif., April 19, 2021 /PRNewswire/ — American Homes 4 Rent (NYSE: AMH) (the “Company”), a leading provider of high-quality single-family homes for rent, today announced that the Company and its operating partnership, American Homes 4 Rent, L.P. (the “Borrower”), successfully closed a $1.25 billion, sustainability-linked revolving credit facility (the “Credit Facility”), amending its existing $800 million revolving credit facility. The amended revolving credit facility provides for expanded borrowing capacity to continue to support the Company’s growth initiatives, reflects a more favorable pricing grid based on current market conditions, and includes a sustainability component based upon third-party performance measures through which overall pricing can further improve if the Company meets certain targets. 

“We are pleased to announce the closing of our upsized credit facility which reflects our continued strategic focus on outsized external growth as well as dedication to sustainability and sound ESG principles,” stated Chris Lau, American Homes 4 Rent’s Chief Financial Officer. “Our flexible balance sheet and access to investment grade capital continue to be a key differentiator for American Homes 4 Rent.  We appreciate the strong support from our bank group and believe the closing of our upsized credit facility reflects their confidence in our future.”

The amended revolving credit facility has an initial maturity date of April 15, 2025 and may be extended for up to one year through the exercise of two six-month extension options at the Borrower’s option if certain conditions are met. As of April 15, 2021$80 million was outstanding under the existing revolving credit facility.

The interest rate on the amended revolving credit facility is at either LIBOR plus a margin ranging from 0.725% to 1.45% or a base rate (determined according to the greater of a prime rate, federal funds rate plus 0.5% or daily LIBOR rate plus 1.0%) plus a margin ranging from 0.00% to 0.45%. In each case the actual margin is determined based on the Company’s credit ratings in effect from time to time.

A total of 15 lenders participated in the Company’s Credit Facility, including Wells Fargo Bank, National Association as Administrative Agent and JPMorgan Chase Bank, N.A. as Syndication Agent. Additional lenders include Bank of America, N.A., PNC Bank, National Association, Raymond James Bank, N.A., Bank of Montreal, Mizuho Bank, LTD., Morgan Stanley Bank, N.A., The Bank of Nova Scotia, U.S. Bank National Association, Citibank, N.A., Regions Bank, City National Bank, Associated Bank, N.A., and BBVA USA as the Sustainability Agent. Wells Fargo Securities, LLC, JPMorgan Chase Bank, N.A., and BofA Securities, Inc. were the Joint Lead Arrangers and Joint Book Runners, and PNC Capital Markets LLC and Raymond James Bank, N.A. were Joint Lead Arrangers.

About American Homes 4 Rent

American Homes 4 Rent (NYSE: AMH) is a leader in the single-family home rental industry and “American Homes 4 Rent” is fast becoming a nationally recognized brand for rental homes, known for high-quality, good value and tenant satisfaction. We are an internally managed Maryland real estate investment trust, or REIT, focused on acquiring, developing, renovating, leasing, and operating attractive, single-family homes as rental properties. As of December 31, 2020, we owned 53,584 single-family properties in selected submarkets in 22 states.

Additional information about American Homes 4 Rent is available on our website at www.americanhomes4rent.com.

Contacts:
American Homes 4 Rent
Investor Relations
Anne McGuinness
Phone: (855) 794-2447
Email: [email protected]

American Homes 4 Rent
Media Relations
Megan Grabos
Phone: (805) 413-5088
Email: [email protected]

View original content to download multimedia:http://www.prnewswire.com/news-releases/american-homes-4-rent-announces-1-25-billion-sustainability-linked-revolving-credit-facility-301270893.html

SOURCE American Homes 4 Rent